Compare · NVO vs SION
NVO vs SION
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sionna Therapeutics Inc. (SION): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SION operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 104.7x SION ($2.06B).
- Over the past year, NVO is down 29.3% and SION is up 130.1% - SION leads by 159.4 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for SION).
- NVO has more recent analyst coverage (25 ratings vs 9 for SION).
- Company
- Novo Nordisk A/S
- Sionna Therapeutics Inc.
- Price
- $48.78+1.22%
- $45.67+3.51%
- Market cap
- $215.95B
- $2.06B
- 1M return
- +2.89%
- +10.96%
- 1Y return
- -29.29%
- +130.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SION
- Director Thompson Peter A. sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)
- Director Orbimed Advisors Llc sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $446,862 worth of shares (10,250 units at $43.60) as part of a pre-agreed trading plan (SEC Form 4)
- Director Thompson Peter A. sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)
- Director Orbimed Advisors Llc sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Director Stelzer Laurie
- SEC Form 4 filed by Director Viney Joanne L.
- SEC Form 4 filed by Director Thompson Peter A.
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Ruddy Marcella K.